Drugs /

loncastuximab tesirine

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.

Clinical Trials

View Clinical Trials for loncastuximab tesirine

Loncastuximab tesirine has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating loncastuximab tesirine, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).

BCL2 Fusion, BCL6 Fusion, and CD19 Expression are the most frequent biomarker inclusion criteria for loncastuximab tesirine clinical trials.

Diffuse large B-cell lymphoma, follicular lymphoma, and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements are the most common diseases being investigated in loncastuximab tesirine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Loncastuximab Tesirine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating loncastuximab tesirine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
adc adct-402, anti-cd19 pbd-conjugate adct-402, adct-402
Drug Target(s) [2]:
CD19
NCIT ID [1]:
C125549

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.